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Abstract: There appear to be two anatomically distinct P- 
endorphin (PE) pathways in the brain, the major one origi- 
nating in the arcuate nucleus of the hypothalamus and a 
smaller one in the area of the nucleus tractus solitarius 
(NTS) of the caudal medulla. Previous studies have shown 
that these two proopiomelanocortin (POMC) systems may 
be differentially regulated by chronic morphine treatment, 
with arcuate cells down-regulated and NTS cells unaffected. 
In the present experiments, we examined the effects of 
chronic opiate antagonist treatment on PE biosynthesis 
across different CNS regions to assess whether the arcuate 
POMC system would be regulated in the opposite direction 
to that seen after opiate agonist treatment and to determine 
whether different BE-containing areas might be differen- 
tially regulated. Male adult rats were administered naltrex- 
one (NTX) by various routes for 8 days (subcutaneous pel- 
lets, osmotic minipumps, or repeated intraperitoneal injec- 
tions). Brain and spinal cord regions were assayed for total 
BE-ir, different molecular weight immunoreactive P-endor- 
phin (PE-ir) peptides, and POMC mRNA. Chronic NTX 
treatment, regardless of the route of administration, re- 
duced total BE-ir concentrations by 30-40% in diencephalic 
areas (the arcuate nucleus, the remaining hypothalamus, 
and the thalamus) and the midbrain, but had no effect on 
PE-ir in the NTS or any region of the spinal cord. At the 
same time, NTX pelleting increased POMC mRNA levels 
in the arcuate to - 140% of control values. These data sug- 
gest that arcuate POMC neurons are up-regulated after 
chronic NTX treatment (whereas NTS and spinal cord sys- 
tems remain unaffected) and that they appear to be under 
tonic inhibition by endogenous opioids. Chromatographic 
analyses demonstrated that, after chronic NTX pelleting, 
the ratio of full length PEI-31 to more processed PE-ir pep- 
tides (i.e., and @El-,,) tended to increase in a dose-de- 
pendent manner in diencephalic areas. Because PE1-31 is the 
only POMC product that possesses opioid agonist proper- 
ties, and has been posited to function as an endoge- 
nous anatgonist of @El-,, , the NTX-induced changes in the 
relative concentrations of PEl-31 and PE,-27/PE1-26 may rep- 
resent a novel regulatory mechanism of POMC cells to alter 
the opioid signal in the synapse. Key Words: Opioids- 
Opiate antagonist-Proopiomelanocortin-P-Endorphin 
processing-Proopiomelanocortin mRNA-Endogenous 
opioids. Bronstein D. M. et al. Pre- and posttranslational 
regulation of @-endorphin biosynthesis in the CNS Effects 
of chronic naltrexone treatment. J. Neurochem. 60,40-49 
(1993). 
Although there is abundant behavioral andpharma- PE-mediated physiological responses and for identify- 
cological evidence to suggest an involvement of the ing functional roles of PE peptides. In the present stud- 
endogenous opioid peptide @-endorphin (PE) in ies, we sought to address two basic issues regarding the 
various physiological functions, there is only minimal regulation of neuronal @E systems. The first issue re- 
information regarding the regulation of @E biosynthe- lates to how PE biosynthesis is altered by changes in 
sis in the CNS. Such information is important for un- neuronal stimulation and the second issue concerns 
derstanding the molecular mechanisms that subserve whether these changes affect all proopiomelanocortin 
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(POMC) neurons in the CNS or whether there are 
regional differences in how PE biosynthesis is regu- 
lated. 
Like most neuropeptides, PE is synthesized as part 
of a larger precursor protein, POMC (Mains et al., 
1977; Roberts and Herbert, 1977~;  Nakanishi et al., 
1979). This adds a great deal of flexibility and com- 
plexity to POMC‘s regulation in the following two 
respects: (1) POMC-derived peptides outside of the 
PE domain [e.g., adrenocorticotropin (ACTH), a-me- 
lanotropin (a-MSH), P-lipotropin (P-LPH)] may have 
interactive effects with PE, and (2) within the PE do- 
main itself, a number of chemically modified forms of 
PE-like peptides are cosynthesized, each with unique 
physiologkal/functional properties that may neutral- 
ize or antagonize @El-31 effects. The biosynthesis of 
BE from POMC involves a series of proteolytic cleav- 
ages and posttranslational modifications that first 
produce P-LPH and subsequently the 3 1 
amino acid sequence at the COOH-terminal end of 
P-LPH (Bradbury et al., 1976; Chretien et al., 1976; 
Mains et al., 1977; Roberts and Herbert, 1977b). 
PEI-31 is subject to further proteolysis at the Lys-Lys 
pair (PE28-@E29), resulting in PEL-,,, which in turn 
can be cleaved to form PE,-,,. Each of these three 
forms of PE (i.e., the 26,27, and 3 1 amino acid forms) 
can be further modified by acetylation at the NH,-ter- 
minus. Interestingly, only PEI-3 possesses properties 
characteristic of classical opiates. Conversion of 
@El-31 to NH,- and COOH-terminal modified forms 
results in peptides that have no effect, or are antago- 
nists, at opioid receptors. Thus, changes in the relative 
concentrations of different immunoreactive P-endor- 
phin (PE-ir) peptides could cause significant changes 
in the opioid “message” transmitted across a synapse. 
The second critical issue to consider in studying the 
regulation of PE-containing neurons relates to PE’s 
localization in anatomically or functionally distinct 
neuronal systems. The distribution of POMC-con- 
taining cells in the CNS can be described in terms of 
rostral and caudal systems. The major POMC system 
is the rostral one, with cell bodies located in and 
around the arcuate nucleus of the mediobasal hypo- 
thalamus and axonal fibers projecting to diverse brain 
regions (e.g., various hypothalamic and thalamic nu- 
clei, the amygdala, septum, and midbrain) (Watson et 
al., 1977, 1978; Bloch et al., 1978; Bloom et al., 1978; 
Nilaver et al., 1979). The smaller caudal POMC sys- 
tem has perikarya scattered in the vicinity of the nu- 
cleus tractus solitarius (NTS) in the medulla oblon- 
gata (Joseph et al., 1983; Schwartzberg and Nakane, 
1983; Bronstein et al., 1992). This cell cluster does not 
appear to have a significant number of rostrally pro- 
jecting fibers; rather, POMC NTS neurons are posited 
to project locally within the brainstem or possibly 
caudally into the spinal cord (Palkovits and Eskay, 
1987; Palkovits et al., 1987; Joseph and Michael, 
1988). There are significant differences across differ- 
ent CNS areas in the extent to which POMC is pro- 
cessed to PE-ir peptide products. In general, process- 
ing is greatest in the rostral POMC system (where p- 
LPH comprises less than 5% and PEI-31 -60% of the 
total BE-ir), least in the spinal cord (larger molecular 
weight BE-ir species represent 560% of total PE-ir and 
PE1-31 as little as lo%), and intermediate in the NTS 
(Zakarian and Smyth, 1982; Dores et al., 1986; Eme- 
son and Eipper, 1986; Gianoulakis and Angelogianni, 
1989; Gutstein et al., 1992). 
Much of what is currently known about the regula- 
tion of PE biosynthesis has been derived from studies 
in the pituitary gland. Results from these studies have 
demonstrated the following two general principles: ( 1) 
Levels of biosynthesis appear coupled to levels of pep- 
tide release, and (2) different biosynthetic mecha- 
nisms (e.g., transcriptional, translational, posttransla- 
tional) are invoked in a time-dependent fashion in the 
process of the cellular coordination of its secretion 
and biosynthetic rates. For example, after acute stimu- 
lation, POMC precursor is translated and processed 
more rapidly than normal, in an apparent short-term 
attempt to replenish depleted peptide stores; after 
chronic stimulation, levels of POMC mRNA in- 
crease, thereby providing cells with larger, long-term 
biosynthetic capacity (Akil et al., 1985; Shiomi et al., 
1 986). Recent data suggest that regulatory principles 
from the pituitary are generalizable to the CNS. For 
example, we (Bronstein et al., 1990) and others (Moc- 
chetti and Costa, 1986; Mocchetti et al., 1989) have 
shown that chronic morphine treatment causes time- 
dependent alterations in multiple parameters of /YE 
biosynthesis in a manner suggesting that morphine 
inhibits PE release and biosynthesis in hypothalamic 
POMC neurons. Although morphine treatment inhib- 
ited hypothalamic POMC neurons, it had no effect on 
PE-ir peptide concentrations in the NTS, and in- 
creased PE-ir levels in the spinal cord (Gutstein et al., 
1990; Bronstein et al., in preparation). These data 
suggest that opiates modulate PE biosynthesis in a re- 
gion-specific manner in the CNS. The goal of the pres- 
ent studies was to examine the effects of chronic nal- 
trexone (NTX) treatment on PE biosynthesis. In light 
of morphine’s inhibitory effects on POMC neurons, it 
was of particular interest to determine whether opiate 
antagonist treatment would up-regulate PE biosynthe- 
sis, thereby implying that POMC neurons are toni- 
cally inhibited by endogenous opioids. We were also 
interested in finding out if NTX would affect PE bio- 
synthesis in a region-specific manner, as was the case 
with morphine. 
MATERIALS AND METHODS 
Animals 
Male Sprague-Dawley rats (Charles River Co., Wilming- 
ton, MA, U.S.A.), weighing 220-250 g at the start of the 
experiments, were maintained in groups of five to six per 
cage in an environmentally controlled room ( 1  2-h light/ 
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dark cycle, lights on at 0600 h) with free access to food and 
water. 
Drug treatments 
Animals received NTX via three different routes of ad- 
ministration. In the first experiment, animals lightly anes- 
thetized with ether were implanted subcutaneously between 
the scapula with two NTX (10 or 30 mg/pellet) or placebo 
(containing Avicel PH- 102, magnesium stearate, silicon 
dioxide, and water) pellets (provided courtesy of the Na- 
tional Institute of Drug Addiction). After 8 days, animals 
were killed by decapitation and the following CNS regions 
were dissected: arcuate, hypothalamus minus the arcuate, 
thalamus, septum, amygdala, midbrain, and caudal me- 
dulla (including the NTS). Spinal cords were divided into 
cervical (CSC), thoracic (TSC), and lumbosacral (LSC) re- 
gions. In the second experiment, anesthetized animals were 
implanted subcutaneously with osmotic minipumps (Alzet, 
Palo Alto, CA, U.S.A.), which released solutions of either 
NTX (70 mg/ml) or distilled water at a rate of 1 Fl/h. Ani- 
mals were killed after 8 days and hypothalami (including 
the arcuate nucleus) were collected. In the third experiment, 
animals received daily subcutaneous injections of NTX (2, 
10, or 20 mg/kg) or saline for 7 days. Twenty-four hours 
after the last injection, animals were killed and hypothalami 
(including the arcuate) were removed. All tissues were fro- 
zen immediately on dry ice and stored at -80°C until as- 
sayed. 
Tissue extractions 
POMC peptides and mRNA were extracted from the 
same tissue using a modified guanidium isothiocyanate 
(GITC) extraction method (Cathala et al., 1983). After ho- 
mogenization in GITC buffer (5.0 M GITC, 8% mercap- 
toethanol, 10 mMEDTA, 50 mMTris, pH 7.5), 6 volumes 
of 4 M LiCl was added and RNA was precipitated overnight 
at 4°C. After centrifugation, RNA and peptides were sepa- 
rated into pellet and supernatant phases, respectively. The 
supernatant was acidified and peptides extracted over C- 18 
Sep-Pak columns (Waters, Milford, MA, U.S.A.). The Sep- 
Pak eluant was dried down, then resuspended in 1 % formic 
acid containing 0.01% bovine serum albumin (BSA). The 
RNA pellets were resuspended in a buffer [50 mMTris, pH 
7.5 ,5  mMEDTA, 0.5% sodium dodecyl sulfate (SDS)] con- 
taining I50 pg/ml of proteinase K and incubated for 1 h at 
43°C. RNA was extracted twice with phenol/chloroform/ 
isoamyl alcohol (50:50: 1, by vol). One-tenth volume of 3 M 
sodium acetate and 2.5 volumes of 100% ethanol were 
added and RNA was precipitated at -20°C. 
Peptide quantitation 
Total PE-ir was determined in the crude extracts of indi- 
vidual animals by radioimmunoassay (RIA) using an anti- 
body directed primarily against ,8E17-27 (Akil et al., 1979). 
Samples were resuspended in RIA buffer (1 50 mM sodium 
phosphate, 1% NaCI, 0.1% BSA, final pH 8.2) and were 
quantitated relative to a camel PE,-3, standard curve. Using 
a primary antibody dilution of 1 :40,000 and 1251-N-acetyl- 
PEI-27 as the trace, the antibody was completely cross-reac- 
tive with 0-LPH, PE,_,,, PE1-26r and their N-acety- 
lated derivatives. It showed no cross-reactivity with other 
POMC-derived peptides such as @El_,,, (3El-,,, des-tyrosine 
ACTH, a-MSH, or y-melanotropin, or with other 
non-POMC-derived opioid peptides [e.g., Leu-enkephalin, 
Met-enkephalin, dynorphin (DYN) A, dynorphin B, a- 
neoendorphin]. Sensitivity of the assay under equilibrium 
conditions was 2-3 fmol/tube, with an IC,, of -20 fmol/ 
tube. 
Gel chromatography 
Gel filtration chromatography followed by BE RIA was 
performed on pooled samples from different experimental 
groups. After aliquots were removed for assay of total PE-ir, 
pooled extracts of two to three animals from each of the 
treatment groups were subjected to gel filtration chromatog- 
raphy to separate PE-ir peptides on the basis of molecular 
weight. Chromatography was performed on a 1.5 X 90-cm 
Sephadex G-50-50 column developed with 1% formic acid 
containing 0.0 1% BSA. Fractions (1.35 ml) were collected 
and vacuum dried for later assay of BE-ir. The column 
was precalibrated with blue dextran, camel P-LPH, camel 
,8EI-3,, camel PE,_,,, and cobalt chloride. 
POMC mRNA quantitation 
POMC mRNA in individual hypothalami was quanti- 
tated by RNase protection and/or northern assays. For both 
techniques, radiolabeled antisense cRNA POMC probe was 
produced by transcribing a linearized pGEM4 plasmid con- 
taining a rat POMC cDNA insert (courtesy of Dr. J. Eber- 
wine), which corresponded to the last 35 bases of intron B 
and the first 395 bases of exon 3 of rat POMC (coding for 
amino acids 19- 150 of the protein precursor). Transcrip- 
tion was performed as described in Promega's technical bul- 
letin (Madison, WI, U.S.A.), using [c~-~'P]UTP as the radio- 
active label and T7 RNA polymerase. 
RNuse protection assuy. Radiolabeled POMC cRNA was 
mixed with aliquots of extracted RNA in hybridization 
buffer [40 m M  piperazine-N,N'-bis(2-ethanesulfonic acid), 
pH 6.4,400 mMNaC1, I .O mM EDTA] and deionized form- 
amide (50%). The mixture was denatured for 5 min at 90"C, 
then incubated at 50°C for 14-18 h. Unhybridized single- 
stranded RNA was digested by ribonuclease A (no. R-5 125, 
Sigma, St. Louis, MO, U.S.A.; 10 mg/ml in RNase buffer, as 
follows: 10 m M  Tris-HCI, pH 7.5, 5.0 m M  EDTA, 0.2 M 
NaCI, 0.1 MLiCI) at 22°C for -60 min. RNaseactivity was 
halted by adding proteinase K (40 mg/ml) in I %  SDS and 
incubating at 37°C for 30 min. Protected cRNA:mRNA 
hybrids were precipitated in ethanol containing 5 Mammo- 
nium acetate and fractionated by electrophoresis on 4% 
polyacrylamide nondenaturing gels in TBE buffer (89 m M  
Tris, 89 m M  boric acid, 2 m M  EDTA). The gels were ex- 
posed via direct contact autoradiography on Kodak X- 
OMAT AR5 film and individual bands were quantitated by 
determining their total integrated optical density using a 
Loats Image Analysis System (Westminster, MD, U.S.A.). 
Northern analysis. Aliquots of total RNA from arcuate 
nuclei of individual animals were electrophoresed on 1.5% 
agarose gels with a HEPES-EDTA/6% formaldehyde run- 
ning buffer. RNA was passively transferred to Nytran filters 
(Schleicher and Schuell, Keene, NH, U.S.A.) and air dried. 
Filters were hybridized in buffer (5% SDS, 400 mMNaPO,, 
1 mM EDTA, 1% BSA, 50% formamide) containing the 
radiolabeled POMC cRNA probe at 60°C for 20 h, washed 
three times in 0.1 X SSC ( 1  5 m M  sodium chloride, 1.5 m M  
sodium citrate), 0.1% SDS, 1 mM EDTA at 70°C and ex- 
posed to x-ray film (Kodak X-OMAT AR5). 
Statistics 
Analyses of variance were performed to assess overall ef- 
fects of NTX, and post hoc paired comparisons were evalu- 
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FIG. 1. Effects of chronic NTX pelleting on total PE-ir in different 
brain and spinal cord regions. Rats were implanted with two NTX 
(10 or 30 mg) or placebo pellets for 8 days, then decapitated. 
Different CNS areas were dissected and assayed for total BE-ir by 
an antibody that recognized the amino acid sequence of PE,,_,, 
(i.e., all PE-ir species were detected). NTX significantly decreased 
PE-ir concentrations in the diencephalon and midbrain (A), but 
had no effect on other brain (B), or spinal cord (C) regions. Values, 
expressed as a percentage of mean placebo concentrations (see 
Results), represent mean I SEM from seven to eight animals. *p 
i 0.05, compared with the placebo-treated control group. 
ated by Duncan’s tests. In all cases, a significance level of 
0.05 was used. 
RESULTS 
Total BE-ir concentrations 
Concentrations of total PE-ir varied as a function of 
the CNS region examined. Basal levels in placebo- 
treated animals were highest in the arcuate nucleus, 
extraarcuate hypothalamus, and septum (92.6 t- 9.1, 
97.8 2 14.4, and 153.2 k 75.3 fmol/mg of tissue, re- 
spectively), and lowest in the spinal cord (3.8 s 1.1, 
3.6 t_ I .  1, and 4.2 t_ 2.0 fmol/mg of tissue in the CSC, 
TSC, and LSC, respectively). PE-ir concentrations 
(fmol/mg of tissue) in other brain regions were inter- 
mediate in value, as follows: thalamus (25.9 f 4.0), 
midbrain (12.7 +- 1.7), amygdala (7.9 S 2.4), and NTS 
(9.1 2 1.9). Chronic NTX treatment altered total PE- 
ir concentrations in a region-specific manner, with 
rostra1 regions generally showing decreases in peptide 
levels, whereas more caudal areas remained un- 
changed. NTX caused significant reductions (30- 
40%) in total PE-ir in the arcuate nucleus (F2,20 
= 18.9, p < 0.000 I), extraarcuate hypothalamus (F2,2, 
= 5.4, p < 0.05), thalamus (F2,,s = 4.6, p < 0.05), and 
midbrain (F2,,8 = 4.7, p < 0.05) compared with pla- 
cebo controls (Fig. iA). A similar decrease was also 
observed in the septum, but due to the large variabil- 
ity, this reduction did not differ significantly from 
control values. Other areas in which NTX had no sig- 
nificant effect on PE-ir concentrations were the amyg- 
dala and NTS (Fig. 1 B) as well as all three levels of the 
spinal cord (i.e., CSC, TSC, LSC; Fig. 1C). It should 
be noted that the two doses of NTX used in this study 
caused comparable changes in PE-ir levels, that is, the 
effects were not dose dependent. The effect of NTX 
did not appear to be specific to its route of administra- 
tion, i.e., repeated daily injections or chronic infusion 
of NTX caused reductions in BE-ir content in the hy- 
pothalamus similar to those found after pelleting (Fig. 
2). Also similar to the pelleting results, the three doses 
of NTX used in the injection study produced consis- 
tent 3540% decreases in PE-ir peptide levels [Dun- 
nett’s t = 4.5, 4.1, and 4.2 (all p < 0.05) for placebo 
versus the 2, 10, and 20 mg/kg doses, respectively; 
Fig. 21. 
Chromatographic separation of different BE-ir 
peptides 
Analyses of brain extracts by molecular sieving and 
RIA revealed that total PE-ir was composed of three 
distinguishable molecular weight species correspond- 
@El-,, could not be resolved from each other on this 
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FIG. 2. Chronic infusion or repeated injections of NTX reduced 
total PE-ir concentrations in the hypothalamus. In one experi- 
ment, animals implanted with osmotic rninipumps were infused 
with NTX (70 rng/ml) or water at a rate of 1 pl/h for 8 days (left). In 
a separate experiment, rats received once daily subcutaneous 
injections of NTX (2, 10, or 20 mg/kg) or saline for 7 days and 
were killed 24 h after the last injection (right). After decapitation, 
hypothalami were dissected and assayed for total PE-ir. Values 
represent the mean & SEM from six animals and are expressed 
as a percentage of control levels (1 74.0 ? 18.4 and 158.1 k 12.4 
fmol/mg of tissue for infusion and injection experiments, respec- 
tively). *p i 0.05, compared with the control group. 
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FIG. 3. Effects of chronic NTX pelleting on different PE-ir peptides in rat brain. Bottom: Representative chromatographs from different 
brain regions depicting changes in BE-ir peptide processing after 8 days of placebo (0 - -0) or 30-mg NTX (0 - -0) pelleting. Pooled 
peptide extracts from different brain regions were loaded on Sephadex G-50-50 columns and developed with 1% formic acid containing 
O.O1°/o BSA. Fractions (1.3 ml) were collected and assayed for BE-ir. Peptide standards for 0-LPH, PE1-3,, and PE1-27 eluted at fractions 
43-47, 59-65, and 64-71, respectively. Under these chromatographic conditions, PE,-ZB coeluted with BE,-27. In addition, the peaks for 
@El..,, and @E,-27/@El-26 contained their N-acetylated derivatives (although acetylated PE-ir peptides represent only minor components of 
all brain regions examined except for the NTS). lop: Effects of chronic NTX pelleting on the relative concentrations of and 
@E,-27/@E1-28 peptides. Total immunoreactivity associated with the PE1-31 and PE146/PE1-27 peaks was calculated and data are expressed 
as the ratio of PE1-31 to PE1-26/PE1-2, concentrations. Values shown represent the mean t SEM of three separate chromatographs (for the 
arcuate and extraarcuate hypothalamus) or the mean and range of two chromatographic runs (all other brain regions). to @E1-27/ 
PE,..26 ratios tended to rise in a dose-dependent manner after NTX pelleting in the three diencephalic brain regions. 
column; Fig. 3). In addition, the N-acetylated deriva- acetylated PE-ir peptides normally comprise only a 
tives of PE,-3,, and PEI-26 would coelute with small proportion of the total PE-ir in the brain areas 
their respective precursor peptides. However, it examined (Zakarian and Smyth, 1 982; Emeson and 
should be kept in mind that, except for the NTS, N- Eipper, 1986). PE-ir associated with each of the three 
TABLE 1. Effects of chronic NTX treatment on absolute amounts Ifemtomoles) of different sized 
PE-ir peptides in various brain regions 
Dose 0-LPH (%) PEI-,I (%) PE1-27/PE1-26 (%I 
Arcuate (n = 3) 0 8.4 * 1.8 170.2 rf: 18.6 133.3 t 1.3 
10 4 . 3 t  2.1 (51) 105.4 k 13.8 (62)" 76.8 2 11.2 (58p 
30 5.8 t 1.4 (69) 116.1 t 10.9 (68) 55.1 k 8.5 (41)" 
10 5.1 1.7 (75) 108.1 k 26.1 (67) 68.0 +- 7.0 (52)" 
30 7.0 t I .9 (103) 101.8 t- 26.1 (64) 48.2 +- 4.3 (37)" 
10 1.3 t 0.5 (260) 147.3 t 3.2(113) 59.2 t 3.3 (71) 
30 0.8 t 0.8 (160) 90.2 ? 3.5 (69) 34.5 k 4.5 (41) 
10 6.9 t 0.6 (70) 250.5 t 10.3 (54) 76.0 k 18.5 (60) 
30 8.5 * 0.1 (87) 273.4 +. 7.4 (59) 90.8 +- 9.1 (72) 
10 ND 114.0 +. 6.0 (101) 52.0 f 36.2 ( I  18) 
30 ND 111.9+.22.1(99) 44.5 & 20.0 (101) 
10 19.2 k 7.1 (155) 123.5 k 5.4 (123) 16.5 f 2.8 (70) 
30 18.9 k 8.2 (152) 101.6 k 7.4 (101) 29.6 k 4.8 (125) 
Hypothalamus (n = 3) 0 6.8 * 0.9 160.5 k 10.2 134.8 2 4.5 
Thalamus (n = 2) 0 0.5 ? 0 130.7 k 2.7 83.1 t 16.7 
Midbrain (n = 2) 0 9.8 +. 1.8 460.8 rt 89.7 126.0 k 11.2 
Amygdala (n = 2) 0 ND 113.3 k 29.3 43.9 k 0.6 
23.6 -t 6.6 NTS (n = 2) 0 12.4 k 3.2 100.3 ? 9.5 
The percentage of total immunoreactivity associated with each of the three peaks observed after gel filtration chromatogra- 
phy (see Fig. 3) was determined for all brain regions examined and then was corrected for the PE-ir concentrations deter- 
mined in crude extracts. Values represent the mean +. SEM for n = 3 (arcuate and extraarcuate hypothalamus) or the mean 
and range for n = 2 (all other brain regions) independent chromatographs. Statistical analyses were performed only on tissues 
with three samples. ND, not detected. 
a p < 0.05 compared with the appropriate 0-dose (placebo) group. 
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FIG. 4. lncrease in hypothalamic POMC mRNA levels after 
chronic NTX infusion as revealed by northern (A) or RNase pro- 
tection (B) analyses. For northern analyses, total RNA was ex- 
tracted from individual hypothalami and electrophoresed on a 
1.5% agarose/formaldehyde gel. After transfer to Nytran filters, 
membranes were probed with a radiolabeled POMC cRNA com- 
plementary to 35 bases of intron B and 395 bases of exon 3 and 
then washed. Membranes were exposed to x-rays for several 
days at -80°C with one intensifying screen. For the RNase pro- 
tection assay, aliquots of total RNA from the same pools used in 
the northern analyses were hybridized with the radiolabeled 
POMC riboprobe. After digestion of single-stranded RNAs by 
RNase treatment, samples were electrophoresed on 4% nonde- 
naturing polyactylamide gels and exposed to x-rays for 8-24 h at 
-80°C with one intensifying screen. 
peaks was calculated for each brain region and experi- 
mental treatment. In addition, the amount of the 
PE,-,, peak was calculated relative to the PE1-27/PE1-26 
peak as a means of estimating changes in opioid ago- 
nist to antagonist/nonagonist activity, respectively. In 
diencephalic areas, chronic NTX treatment generally 
decreased the amounts of different POMC-derived 
peptides (Table 1 ; Fig. 3). Immunoreactivity asso- 
ciated with the BE,-31 peak was decreased by both 
NTX doses to -65% of control levels in the arcuate, 
extraarcuate hypothalamus, and thalamus, whereas 
the @El-27/PE1-26 peak decreased -40% and -60% 
with the 10- and 30-mg NTX pelleting, respectively 
(Table 1). The relatively larger reductions in BE,-,,/ 
PE1-26 levels caused the ratios of PE,-,, to PE,-,7/ 
to increase in the arcuate, extraarcuate hypo- 
thalamus, and thalamus; maximal effects were ob- 
served with the 30-mg NTX pellets, where ratios 
increased approximately twofold (Fig. 3). In the mid- 
brain, 10- or 30-mg NTX pellets caused proportion- 
ately similar decreases in the PE,-,,- and 
PE,-,,-size peaks, with the result that 1-31 to 1-27/1- 
26 ratios did not change (Table 1 ; Fig. 3). In the amyg- 
dala, NTX had no effect on any of the BE-ir species. 
Caudal POMC structures also seemed unaffected 
by NTX pelleting. In the NTS, the amounts of differ- 
ent @E-ir peptides and their ratios were comparable in 
placebo- and NTX-treated animals (Table 1; Fig. 3). 
In addition, there did not appear to be any effect of 
NTX on PE processing in any spinal cord region (data 
not shown). However, the latter data can be consid- 
ered preliminary because the limited amount of PE-ir 
in the spinal cord allowed us to perform chromato- 
graphic analyses only once per region. 
POMC mRNA quantitation 
POMC mRNA in the arcuate nucleus was quanti- 
tated in three separate studies that differed primarily 
in NTX’s route of administration (i.e., via pelleting, 
continuous infusion, or repeated intraperitoneal in- 
jections). In most cases, POMC mRNA in individual 
samples was quantitated by both northern and RNase 
protection analyses. Data from the continuous infu- 
sion experiment illustrate that the two techniques gen- 
erally yielded comparable results (Fig. 4). Autoradio- 
graphic bands from the northern analyses were quan- 
titated by optical densitometry and the data from 
each of the three studies are shown in Fig. 5. With all 
three routes of administration, POMC mRNA levels 
in NTX-treated animals were 30-4070 higher than 
those found in control animals, although the increases 
reached statistical significance only in the pelleting 
(F2,* = 5.9, p < 0.05) and osmotic minipump (t,,, 
= 2.5, p < 0.05) experiments. 
DISCUSSION 
The following were the three main findings in these 
studies: ( 1 )  NTX appeared to up-regulate PE biosyn- 
thesis and release in arcuate POMC neurons, as evi- 
denced by decreases in PE-ir concentrations and in- 
creases in POMC mRNA levels. (2) The effects of 
NTX on POMC biosynthesis were region specific. 
Whereas arcuate POMC cells were apparently up-reg- 
dated, NTX had no effect on PE-ir peptides in the 
NTS or spinal cord. Within the rostra1 POMC system 
itself, there were regional differences in the effects of 
NTX. (3) Chronic NTX treatment appeared to in- 
crease PEI-3, to @E1-27/PE1-26 ratios in diencephalic 
I Placebo Naltrerone 
4 0 4  * 
ROUTE OF ADMINISTRATION 
FIG. 5. Effects of chronic NTX treatment on POMC mRNA levels 
in the arcuate/hypothalamus. NTX was administered to animals 
by pellets (1 0 mg/pellet), osmotic minipump (70 pg/h), or repeated 
injections (1 0 mg/kg) as described in the legends for Figs. 1 and 
2. Total RNA from individual animals was processed by northern 
analysis and specific POMC mRNA bands were quantitated by 
densitometry. Data represent the mean (kSEM) relative optical 
density of six to eight animals. *p < 0.05. compared with the 
placebo-treated control group. 
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brain areas. We speculate that these shifts in peptide 
forms could represent a novel regulatory mechanism 
of POMC cells whereby changes in opioid tone could 
be effected by cleaving the opioid agonist BEle3, to an 
antagonist form 
First, in agreement with previous results (Ragavan 
et al., 1983), we found that NTX markedly reduced 
total PE-ir concentrations to approximately two- 
thirds of control levels in most rostral brain regions 
examined. It is important to note that steady-state 
measures of peptide concentrations reflect an equilib- 
rium between the rates of peptide biosynthesis and 
peptide release. Hence, in the absence of other infor- 
mation, it is impossible to know whether NTX treat- 
ment lowered PE-ir levels by increasing the rate of 
peptide release or degradation or by decreasing PE 
biosynthesis. Results from a second measure of bio- 
synthetic activity, showing that POMC mRNA levels 
were elevated in NTX-treated animals, suggest that 
overall biosynthesis of BE was stimulated by chronic 
NTX treatment. Presumably, these increases in ar- 
cuate POMC mRNA represent a compensatory re- 
sponse to increased peptide release. That steady-state 
PE-ir concentrations were reduced at the same time 
that POMC mRNA levels were increased could be 
explained if the biosynthetic rate had not yet ade- 
quately compensated for the increased rate of peptide 
release. We have interpreted the pattern of changes in 
BE peptide and POMC mRNA concentrations as in- 
dicating that NTX activates POMC neurons in the 
arcuate nucleus, stimulating both PE release and bio- 
synthesis. The present data complement well the re- 
sults of earlier studies, which suggest that chronic 
morphine treatment inhibits PE release and biosynthe- 
sis in the hypothalamus (Mocchetti and Costa, 1986; 
Mocchetti et al., 1989; Bronstein et al., 1990). The 
present results, showing that an opiate antagonist ap- 
parently induces PE biosynthesis, suggest that POMC 
neurons in the arcuate nucleus are tonically inhibited 
by endogenous opioids. 
It is interesting that the effects of opiate agonists 
and antagonists on POMC biosynthesis are similar to 
those reported for the two other opioid peptide fami- 
lies, prodynorphin (Pro-DYN) and proenkephalin. 
Previous studies have demonstrated that chronic 
morphine treatment down-regulates (Uhl et al., 
1988), and chronic NTX up-regulates (Tempel et al., 
1990), enkephalin biosynthesis in the striatum. Simi- 
larly, striatal Pro-DYN mRNA has been found to de- 
crease after chronic morphine exposure and increase 
after chronic naloxone treatment (Romualdi et al., 
1990, 1991). Thus, it appears that all three opioid 
peptide families are regulated in a similar fashion by 
opiate agonist or antagonist treatment. Romualdi’s 
group has further shown that the effects of chronic 
treatment with K-OpiOid receptor agonists (ethylketo- 
cyclazocine or U50,488H) on Pro-DYN message are 
comparable with those found with morphine (Ro- 
mualdi et al., 1990), suggesting that K-receptor-selec- 
tive endogenous ligands, such as DYN A (Chavkin et 
al., 1982; Spampinato and Candeletti, 1985), might 
be involved in regulating the activity of DYN neu- 
rons. Experiments using specific opiate receptor ago- 
nists and antagonists will help in determining the en- 
dogenous opioids and receptor types involved in regu- 
lating POMC neurons. In this regard, it was recently 
reported that various endogenous opioid peptides 
(including Met- and Leu-enkephalin, and 
DYN,-,) appear to act via 6-, K-, and CT- (but not p-) 
receptors to down-regulate POMC mRNA in cul- 
tured hypothalamic neurons (I’Hereault and Barden, 
199 1). 
The second major point derived from these studies 
relates to NTX causing region-specific changes in PE 
biosynthesis. To begin with, not all brain areas inner- 
vated by arcuate POMC neurons responded in the 
same manner to chronic NTX treatment. In terms of 
total PE-ir, the amygdala was conspicuous in showing 
no effects of NTX, whereas other rostral brain regions 
exhibited 30-40% decreases in PE-ir. Because of the 
high variability in the septum data, it was unclear 
whether this region was also affected by NTX pellet- 
ing. Until future studies resolve this point, the septum 
and amygdala may be viewed as unique among rostral 
POMC regions in that they appear to be unaffected by 
chronic NTX treatment. The effects of NTX on the 
relative concentrations of and PE1-27/PE1-26 
also appear to be region specific. Whereas PE1-31 to 
PE1-27//3E1-26 ratios tended to increase dose depen- 
dently in diencephalic areas, this was not the case in 
the midbrain, even though this area had a reduction 
in total PE-ir similar to that seen in the arcuate, hypo- 
thalamus, or thalamus. One explanation for region- 
specific effects of NTX within the rostral POMC sys- 
tem is that there may be anatomically distinct subpop- 
ulations of arcuate POMC neurons, some of which 
project to diencephalic areas and others which project 
to the midbrain, septum, and/or amygdala. These dif- 
ferent POMC pathways may then be differentially reg- 
ulated by NTX. There are anatomical and pharmaco- 
logical data that directly or indirectly suggest that sub- 
sets of arcuate POMC cells can be defined in terms of 
unique nerve terminal projections, regulation, or 
function (Wilcox et al., 1986; Yoshida and Taniguchi, 
1988; Bronstein and Akil, 1989). Alternatively, it 
could be postulated that opioid ligands regulate PE-ir 
peptide release and/or processing presynaptically and 
that the region-specific effects observed after NTX are 
due to differences in the opioid inputs into different 
POMC nerve terminal regions. Unfortunately, the an- 
atomical data do not distinguish between these possi- 
bilities at the present time. Three major fiber projec- 
tional systems (rostral, lateral, and caudal) have been 
described for POMC perikarya in the arcuate nucleus 
(Khachaturian et al., 1985). With the possible excep- 
tion of the septum, every POMC nerve terminal area 
in the CNS may be innervated by at least two of these 
pathways. Regardless of the mechanism, however, the 
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present data reinforce the notion that the arcuate 
POMC cell group is not a homogeneous system. 
The present results suggest that, in general, rostral 
and caudal POMC systems are differentially affected 
by chronic opiate antagonist treatment. Although sev- 
eral rostral brain structures showed a change in at 
least one aspect of POMC biosynthesis, the NTS and 
all three levels of the spinal cord appeared to be unaf- 
fected by NTX. (We should note that NTX did reduce 
total PE-ir in the TSC by -40%, but this difference 
was not statistically significant because of high vari- 
ance in the placebo group.) Previous studies have dem- 
onstrated that the rostral arcuate-derived POMC sys- 
tem is anatomically separate from caudal POMC neu- 
rons (although the converse is not equally true as 
some PE-ir nerve terminals in the medulla are derived 
from arcuate neurons) (Palkovits and Eskay, 1987; 
Palkovits et al., 1987; Joseph and Michael, 1988). The 
present data, showing rostral-caudal differences in 
the effects of NTX on PE biosynthesis, suggest that 
not only are rostral and caudal POMC systems ana- 
tomically distinct, they may also be regulated in neu- 
rochemically different ways. Although the present 
data demonstrate that the NTS and spinal cord were 
similarly insensitive to NTX’s effects, these two areas 
have been previously shown to differ in their response 
to chronic opiate agonist treatment. Consistent in- 
creases in total PE-ir were observed throughout the 
spinal cord after 7 days of morphine treatment; at the 
same time, PE-ir levels in the NTS remained un- 
changed (Gutstein et al., 1990; Bronstein et al., in 
preparation). Taken together with the results of these 
studies, the data suggest that although BE-ir peptide 
levels in the spinal cord can be altered by opioid ago- 
nists, they do not appear to be tonically inhibited by 
endogenous opioids (in contrast to arcuate POMC 
neurons). 
The unique pattern of effects of opiate agonists and 
antagonists on PE peptides in the spinal cord provides 
support for the idea that there may be intrinsic POMC 
neurons in the spinal cord. Gianoulakis and Angelo- 
gianni (1989) have shown that the mixture of BE-ir 
peptides in the spinal cord is unique in the CNS (i.e., 
POMC appears to undergo far less processing than in 
more rostral CNS regions). Recent data in our labora- 
tory, showing that some PE-ir remains in thoracic and 
sacral segments of the spinal cord even after complete 
transection at higher spinal cord levels, further sup- 
port the possibility of intrinsic POMC neurons in the 
spinal cord (Gutstein et al., 1992). The finding that 
the opiate regulation of PE-ir peptides in the spinal 
cord may differ from the arcuate or NTS POMC sys- 
tems is consistent with the idea that some POMC so- 
mata exist in the spinal cord. It should be pointed out, 
however, that this idea is not supported by immunocy- 
tochemical data, which revealed the presence of 
POMC peptide-containing nerve fibers and termi- 
nals, but no cell bodies, in the spinal cord of the adult 
rat (Khachaturian et al., 1985; Tsou et al., 1986). 
One of the most intriguing observations in these 
experiments was the apparent change in the relative 
concentrations of @El-31 and PE1-27/@1-26 after 
chronic NTX pelleting. The ratio of these peptides 
provides an estimate ofthe relative amounts of opioid 
agonist and antagonist/nonagonist in different brain 
regons. In the arcuate, extraarcuate hypothalamus, 
and thalamus, PEI-31 to PEl-27/PE1-26 ratios increased 
as a result of proportionately larger NTX-induced de- 
creases in PE1-27/PE1-26- versus PE,-31-size peptides. 
Maximal effects, produced by the 30-mg pellets, re- 
sulted in 1-31 to I-27/1-26 ratios nearly doubling. 
An interesting question is whether the higher ratios 
result from changes in PE-ir processing or, perhaps, to 
peptide-selective changes in degradation or release. 
Regardless of the mechanism, alterations in the rela- 
tive concentrations of differently processed PE-ir pep- 
tides could have important functional, consequences 
because each peptide form has unique pharmacologi- 
cal/physiological properties (see Young et al., 1992). 
For example, although PE1-31 possesses classical 
opiate-like properties, PE,-,, appears to act as an en- 
dogenous antagonist of many of the effects of @El-31. 
In addition to competing with PEI-3, for opiate bind- 
ing sites (Akil et al., 198 I), administration of @El-27 
attenuates or completely blocks the opioid actions of 
PE1-31 in a variety of paradigms including analgesia 
(Deakin et al., 1980; Hammonds et al., 1984), rein- 
forcement (Bals-Kubik et al., 1988), Met-enkephalin 
release (Tseng and Li, 1986), and cardiovascular re- 
sponses (Hirsch et al., 1988, 1990). Because proteoly- 
sis of PE1-31 to @El-27 changes the peptide from a re- 
ceptor agonist to antagonist, even small changes in 
the relative concentrations of these two compounds 
could have profound effects on the amount of opioid 
signal transmitted across a synapse. Previously, mor- 
phine pelleting was found to decrease the PE,-32 to 
PE1-27/PE1-2, ratio, suggesting that endogenous opioid 
activity may have been functionally decreased (Bron- 
stein et al., 1990b). The increase in PE1-3, to PEl-27/ 
PE1-26 ratios observed here after chronic treatment 
with NTX implies that there may be greater opioid 
tone in diencephalic POMC nerve terminals of NTX- 
treated animals compared with control animals. 
There have been reports that animals treated chroni- 
cally with opiate antagonists display hypersensitive 
responses in opioid-mediated functions such as anal- 
gesia (Bardo et al., 1984; Tempe1 et al., 1985; Yoburn 
et al., 1985). Although antagonist-induced up-regula- 
tion of opiate receptors is likely to play an important 
role in this increased sensitivity, the present data sug- 
gest that changes in endogenous opioid peptide forms 
may also contribute to this effect. 
In summary, we found that chronic treatment with 
NTX altered several parameters of POMC biosynthe- 
sis in the rostral arcuate system, suggestive of an up- 
regulation of BE biosynthesis and release in these neu- 
rons. In addition, NTX appeared to alter the relative 
amounts of opioid agonist and antagonist/nonagonist 
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PE-ir peptides in diencephalic areas such that endoge- 
nous opioid tone may have increased. In contrast to 
its effects on the arcuate POMC system, NTX caused 
no apparent changes in PE-ir peptides in the NTS or 
spinal cord. Taken together with previous work, 
showing inhibitory effects of opiate agonists on PE 
biosynthesis, the evidence suggests that endogenous 
opioids regulate the activity of a subpopulation of 
POMC neurons in the arcuate nucleus. 
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